Aptevo Therapeutics Inc. (APVO) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology candidates using its ADAPTIR and ADAPTIR-FLEX platforms. Key clinical candidates include mipletamig (formerly APVO436) for acute myelogenous leukemia (AML) and ALG.APV-527 for solid tumors. The company is a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(5.1) million | $(6.3) million | $(17.8) million | $(11.5) million |
| Net Loss Per Share (Basic/Diluted) | $(0.48) | $(22.16) | $(5.01) | $(56.22) |
| Operating Expenses (R&D) | $(3.1) million | $(3.9) million | $(10.5) million | $(13.5) million |
| Operating Expenses (G&A) | $(2.1) million | $(2.7) million | $(7.7) million | $(9.0) million |
| Cash and Cash Equivalents | $7.8 million | $19.1 million | $7.8 million (End of Period) | $19.1 million (End of Period) |
| Accumulated Deficit | $(241.3) million | $(217.5) million | $(241.3) million | $(217.5) million |
| Net Cash Used in Operating Activities | N/A | N/A | $(18.0) million | $(6.5) million |
| Net Cash Provided by Financing Activities | N/A | N/A | $8.9 million | $3.0 million |
Note: Revenue is $0 as the company has no approved commercial products. The significant decrease in Net Loss Per Share year-over-year is primarily due to a 1-for-44 reverse stock split effective March 5, 2024, which increased the share count used in the denominator.
Material Changes vs. Prior Period
- Cost Reductions: Research and Development (R&D) expenses decreased by $0.8 million in Q3 and $3.0 million YTD compared to 2023. This was driven by lower spending on the mipletamig clinical trial (concluding Phase 1b dose expansion) and reduced preclinical project costs. General and Administrative (G&A) expenses also declined due to lower employee and consulting costs.
- Capital Structure: The company completed a 1-for-44 reverse stock split in March 2024. Significant equity financing occurred in 2024, including a public offering in April and registered direct offerings in July and September, raising approximately $8.9 million in net proceeds YTD.
- Liquidity: Cash and cash equivalents decreased from $16.9 million at year-end 2023 to $7.8 million at September 30, 2024, reflecting a net cash burn of $18.0 million from operations.
- Discontinued Operations: Unlike the prior year, which included $0.9 million in income from discontinued operations (related to IXINITY milestones), there was no income from discontinued operations in the current period.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for one year from the date of issuance (through August 2025). The company requires additional funding to support operations and clinical development.
- Financing Activity: The company raised capital through multiple offerings in 2024. In September 2024, a registered direct offering raised $3.0 million gross proceeds. Warrant modifications were executed to reduce exercise prices to $0.33 and $0.515 per share for certain holders.
- Listing Compliance: The company received a Nasdaq deficiency notice in June 2024 regarding the minimum bid price requirement (stock trading below $1.00). The company has until December 23, 2024, to regain compliance, potentially via a reverse stock split. Stockholders approved a reverse split authorization (1-for-5 to 1-for-37) in October 2024.
- Clinical Progress: The company initiated the "RAINIER" Phase 1b/2 dose optimization trial for mipletamig in August 2024. Data from the ALG.APV-527 Phase 1 monotherapy trial showed 60% of evaluable patients achieved stable disease.
- Risks: Key risks include the inability to raise additional capital, potential delisting from Nasdaq, clinical trial failures, and reliance on third-party manufacturers and collaborators (e.g., Alligator Bioscience for ALG.APV-527).
Investor Verification Checklist
- Cash Runway: Verify the current cash balance ($7.8 million) against the burn rate (~$6 million/quarter) to assess the immediate need for capital.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by December 23, 2024, or confirm the execution of a reverse stock split.
- Warrant Overhang: Review the significant number of outstanding warrants (over 36 million) and their low exercise prices ($0.33 - $0.515) to understand potential future dilution.
- Clinical Milestones: Track enrollment and data readouts for the mipletamig RAINIER trial and ALG.APV-527 Phase 1 study.
- Going Concern Status: Review subsequent filings for any new financing announcements or strategic partnerships that might alleviate the going concern warning.